OSR HOLDINGS INC (OSRH)
NASDAQHealth CareBiotechnologySnapshot 2026-09-15
$0.28+136.05%
Close 2026-08-31 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-15
Research Workspace
Put OSRH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar broken — Improve financial performance and reduce losses: Net loss ~$1.0M (2026-Q2) vs <$3M target; Q1 loss ~$3.5M.
View ThesisMiddle-of-the-pack management execution.
View ManagementThis stock is highly volatile — it swings about 4% on a typical day and fell roughly 88% in its worst 12-month stretch.
View RiskOSRH's growth depends on improving financial performance and reducing losses. Recent results show a net loss of about $1.0 million, which is above the target of less than $3 million. The company trades at 5.2× price-to-sales, below the peer median of 11.2×. This suggests the price is roughly in line with the growth forecast. The primary risk is the need to improve financial performance, as the recent loss is a significant concern. Peer multiples imply a price about 5% below where it trades. Our read is provisional.
Trailing returns as of 2026-08-31. OSRH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering OSRH (as of Aug 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare OSRH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| OSRH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put OSRH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-08-31. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.